TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06665165: AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

Sponsor: Amylyx Pharmaceuticals Inc. · Phase: PHASE1 · Area: RARE_ORPHAN · Target Enrollment: 48 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,926,100

Rescue Site Savings

+$1,260,720

Unlock Full NCT06665165 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06665165 Rescue Dossier →